HINJ and New Jersey's Life Sciences Community Brochure

Download HINJ and New Jersey’s Life Sciences Community


To learn more about our
Life Sciences industry,




Save the Date! HINJ to Host 2016 Life Sciences Celebration on October 6 in Trenton

Celebration HINJ

Please mark your calendar to join HINJ in honoring meritorious leadership in and contributions to New Jersey’s life sciences community at HINJ’s 2016 Life Sciences Celebration, which will be held Thursday, October 6 from 8:00 to 10:00 a.m. at the Historic Trenton Masonic Temple.

Additional information — including HINJ’s 2016 honorees and online registration — will be announced shortly.

For the full story, which includes past HINJ honorees, click here.

HINJ Announces New Board and Steering Committee Leadership; BD’s Jeffrey Sherman Named Board Chair

Jeffrey S. Sherman

Jeffrey S. Sherman

Jeffrey S. Sherman, Executive Vice President and General Counsel, BD (Becton, Dickinson and Company), has been named Chair of the HINJ Board of Trustees.  He previously served as Treasurer of the HINJ Board.

Mr. Sherman succeeds Craig B. Bleifer, Vice President, General Counsel and Secretary, Daiichi Sankyo, Inc.  Mr. Bleifer continues to serve the HINJ Board as its Treasurer.

The HINJ Board elected two Vice Chairs: Yin C. Becker, Vice President, Communications and Public Affairs, Stryker, and Mark J. Alles, Chief Executive Officer, Celgene Corporation

HINJ also announced that Wendy M. Lazarus, Director, State Government Relations, Pfizer Inc., will continue to serve as the Chair of the HINJ Steering Committee.  Todd Spangler, Director, Public Policy & Government Relations, BD, will serve as Vice Chair.

For the complete story, please click here.

New Jersey to Showcase Its Life Sciences Leadership at BIO International 2016BIO Pavilion 2016 Booth

New Jersey will showcase more than 20 organizations, including top companies, universities, trade associations, State government and Choose New Jersey, Inc. at the New Jersey Pavilion (Booth #6544, North Exhibition Hall) at Bio International 2016, the world’s largest biotechnology conference.

From June 7-9, the New Jersey delegation — including HINJ — will meet with European, Canadian and Australian business executives from life science-based organizations interested in learning what makes the State a perfect place to start or relocate their bio-related firm.

HINJ is the lead sponsor of Choose New Jersey’s reception on Tuesday evening at which guests will learn of the strategic advantages of a New Jersey location for their life sciences companies.

For the complete story, please click here.

HINJ and Other New Jersey Healthcare Leaders Hold Summit on Key Challenges

(L. to r.)  HINJ's Dean Paranicas, MSNJ's Larry Downs, NJAHP's Ward Sanders and NJHA's Betsy Ryan

(L. to r.) HINJ’s Dean Paranicas, MSNJ’s Larry Downs, NJAHP’s Wardell Sanders and NJHA’s Elizabeth Ryan

Members of the state’s various healthcare communities — hospitals, health plans, physicians and life sciences — gathered for the New Jersey Healthcare Stakeholders Summit on April 21 for a daylong event to discuss the key challenges facing the healthcare delivery system.

The event was a joint effort of HINJ, the Medical Society of New Jersey (MSNJ), the New Jersey Association of Health Plans (NJAHP) and the New Jersey Hospital Association (NJHA)

HINJ President and Chief Executive Officer Dean Paranicas said, “Our healthcare ecosystem is comprised of different sectors, each with its unique perspective and focus that sometimes produces shared and other times divergent views on healthcare issues.  However, all of these sectors are focused on the same goal: helping patients.”

“Today’s event,” Paranicas continued, “demonstrates a collaborative approach to exploring new ways of working together to benefit patients and our entire healthcare system in aggregate.”

For the complete story, please click here.


PharmFest at Montclair University

PharmFest 2016, a biennial forum presented by Montclair State University in partnership with HINJ, was held on Wednesday, April 13 at the MSU’s Conference Center. 

With the theme of “The Value of Innovation,” PharmFest 2016 explored emerging issues and trends impacting the biopharmaceutical, health and medical technology sectors and to broaden awareness of the current and future state of the industry. 

John Crowley, Chairman and CEO, Amicus Therapeutics, Inc., and Brian Gragnolati, President and CEO, Atlantic Health Systems, keynoted.  

HINJ’S ‘By the Numbers’ Portal Showcases Life Sciences’ NEW JERSEY Economic Impact

Economic Development 2HINJ has updated “New Jersey Life Sciences: By the Numbers,” the association’s compilation of information from HINJ and third-party sources on the life sciences sector’s significant impact on New Jersey’s economy.

HINJ’s By the Numbers includes economic-impact data from a number of resources, including the New Jersey Department of Labor & Workforce Development, the Food and Drug Administration, the Biotechnology Innovation Organization (BIO), the Pharmaceutical Research and Manufacturers of America (PhRMA), Choose New Jersey and We Work for Health New Jersey, among others.

HINJ’s expanded By the Number page is the latest offering on HINJ.org, which was relaunched in February 2013 as part of HINJ’s strategic plan to build a dynamic communications capability that delivers relevant, robust and timely information to internal and external stakeholders.

For the complete story, please click here.

HINJ Co-SponsorS Rare Disease Day 2016; Focus on Building Relationships, Raising Awareness in Trenton

Rare Disease Day

HINJ partnered with the New Jersey Rare Disease Alliance (NJRDA) on its activities to recognize Rare Disease Day 2016 on February 29 at the New Jersey Business and Industry Association (NJBIA) in Trenton.

The half-day event was also co-sponsored by BioNJ and the National Organization for Rare Diseases (NORD).

Speaking at the event, HINJ President and Chief Executive Officer Dean J. Paranicas emphasized the importance of a collaborative effort in building relationships with, and educating, policymakers, both in Trenton and Washington, DC.

For the complete story, click here.

HINJ’s Berman Named to Chair NJBIA’s Innovation and Technology Committee

Innovation button touch 2

HINJ Senior Vice President – State Affairs Haskell Berman has been named as chair of New Jersey Business & Industry Association (NJBIA) newly created Innovation and Technology Policy Committee.

The committee will develop and advocate for policies that promote investment in research and development, collaboration between industry and higher education institutions, and entrepreneurship that will proliferate New Jersey’s standing as a global research hub and retain the economic benefits on which the state has come to rely.

The committee will complement the work of Innovation New Jersey, a coalition that was co-founded in 2010 by HINJ and NJBIA.

For the complete story, click here.

HINJ Statement on Passage of the Omnibus Spending Package

Capitol Building flag

HINJ on December 18 congratulated Congress on the passage of legislation that includes several key provisions that will strengthen medical innovation in the United States. 

The spending measure, which received bipartisan support, includes $2 billion in increased funding for the National Institutes of Health (NIH); a $133 million increase in funding for the Food and Drug Administration (FDA); a two-year suspension of the medical device excise tax; and makes permanent the Research & Development (R&D) tax credit.

HINJ President and Chief Executive Officer Dean J. Paranicas said, “We are grateful to New Jersey’s Congressional Delegation for their significant work on these important provisions that foster the innovation environment to research and discover the next generation of treatments and cures.”

“This legislation will greatly benefit patients awaiting advances in medical care, improves global human health, and strengthens New Jersey’s innovative ecosystem and jobs,” Paranicas continued.  “We look forward to its enactment.”

HINJ, Rx4NJ and WWFH-NJ Host ‘The Value of Medical Innovation: Saving Lives, Saving Money’ Policy Forum

Dean Paranicas and PhRMA’s Dr. Michael Ybarra

HINJ, the Rx4NJ Partnership and We Work for Health New Jersey (WWFH-NJ) hosted a health policy forum on December 15 that focused on “The Value of Medical Innovation: Saving Lives, Saving Money.”  Speakers were:

Dr. Ybarra and Paranicas presented a fact-driven presentation of PhRMA’s “Prescription Medicines:  Costs in Context.”

For the complete story, click here.

NJTV News Explores Prescription Drug Prices in the U.S.; HINJ CEO Dean Paranicas Interviewed

NJTV News w Mary Alice Williams

In a segment broadcast on December 4, NJTV News explored prescription drug prices in the U.S. and consumer concerns.

HINJ President and Chief Executive Officer Dean J. Paranicas told correspondent Erin Delmore, “So much of the cost of those drugs is offset by rebates, discounts, coupons and the like, in terms of what the true cost of the drug is.”

Paranicas pointed out that medication costs include the price of innovation.  “Drug development is an incredibly expensive, incredibly risky, incredibly lengthy process,” he said.

“The typical prescription drug takes on average $2.6 billion and 12 to 15 years to develop,” Paranicas said.  “Now, that just represents the drug that actually succeeds in getting into the marketplace.  Only about 12 percent of the drug candidates that even get into clinical trials are ultimately approved by the FDA.” 

To read the complete story, click here.  To view the NJTV News segment, click here.

HINJ and NJ Life Sciences Vendors Alliance Host 2015 Procurement Conference


HINJ and the New Jersey Life Sciences Vendors Alliance’s (NJLSVA) hosted the 2015 Annual Procurement Conference on November 11 at Forsgate Country Club in Cranbury, New Jersey

Co-sponsored by the MID Jersey Chamber of Commerce, speakers at the half-day event were:

  • David McCarthy, Senior Director, PGS Procurement – Americas, Pfizer, Inc.
  • Patrick Murray, Director, Monmouth University Polling Institute
  • The Honorable Declan O’Scanlon, Republican Budget Officer, New Jersey General Assembly
  • Dean J. Paranicas, President and Chief Executive Officer, HINJ
  • The Honorable Bob Prunetti, President, MID Jersey Chamber of Commerce
  • Donald Sico, Executive Director, NJLSVA

For the complete story, click here.

HINJ Honors Four at Life Sciences Celebration 2015: Rep. Lance, Dr. Nils Lonberg, Deborah Brown, David Knowlton

(L. to r.) HINJ President and CEO Dean Paranicas, Deborah Brown, Scott Knowlton, Rep. Leonard Lance, Dr. Nils Lonberg and HINJ Chair Craig Bleifer

(L. to r.) HINJ President and CEO Dean Paranicas, Deborah Brown, Scott Knowlton, Rep. Leonard Lance, Dr. Nils Lonberg and HINJ Chair Craig Bleifer

HINJ honored meritorious leadership in and contributions to New Jersey’s life sciences community at its 2015 Life Sciences Celebration, which was held October 30 at the Wyndham Garden Trenton.

HINJ’s 2015 honorees were:

  • The Honorable Bob Franks Public Service Award: Leonard Lance (R-7), Member, US House Energy and Commerce Committee
  • Research: Nils Lonberg, Ph.D., Senior Vice President, Oncology Discovery Biology, Bristol-Myers Squibb Company
  • Patient Advocacy: Deborah P. Brown, President and Chief Executive Officer, American Lung Association of the Mid-Atlantic
  • Special Recognition: David L. Knowlton, President and Chief Executive Officer, New Jersey Health Care Quality Institute

For the complete story, click here.

HINJ Launches ‘Value of Medical Innovation’ Website Section; Focuses on Saving Lives — And Saving MoneYInnovation value of medical innovation

HINJ has updated its online portal at HINJ.org to present Value of Medical Innovation, a fact-driven, consumer-friendly digital library that delves into the myriad benefits of medical innovation, which saves lives — and saves money.

HINJ’s Value of Medical Innovation presents statistics from a number of resources, including the U.S. government, AdvaMed, BIO, PhRMA and various medical research organizations.

In November 2014, HINJ added a Corporate Social Responsibility section to its website that focuses on HINJ member companies’ Corporate Social Responsibility (CSR) activities.

To visit HINJ’s newest online offering, click on the Value of Medical Innovation tab at the top of this page or click here.

For the complete story, click here.

HINJ and NJBIA Celebrate Innovation NJ’s FIFTH Anniversary; Looks Back at — and Forward to — Growing NJ’s Innovation Ecosystem

Five years ago, two of New Jersey’s top business organizations — NJBIA and HINJ — joined forces to promote greater collaboration between higher education and business so New Jersey could enjoy the economic benefits of an innovation ecosystem.

On October 1, Innovation New Jersey — a diverse coalition of industry, higher education and government — celebrated its five-year anniversary with a look back at what has been accomplished since its founding, and a peek into the future as to where New Jersey’s innovation ecosystem is headed.

To commemorate New Jersey’s success, the New Jersey Policy Research Organization (NJPRO) Foundation released its latest report, “The Road to an Innovation Ecosystem: Highlights from the Past Five Years.”

For the complete story, click here.

HINJ Updates Portal of Member Companies’ Corporate Social Responsibility and Sustainability Activities

CSR chasing arrows

HINJ has updated its online portal to HINJ member companies’ myriad corporate social responsibility (CSR) activities, including their corporate philanthropy, patient outreach initiatives and sustainability/green practices

Launched in November 2014 and promoted via Twitter, Facebook and LinkedIn, HINJ’s CSR online portal has become one of the most-visited areas of our website

The portal — “HINJ Members’ CSR Activities” — is accessible by clicking on the second tab under the HINJ homepage’s Corporate Social Responsibility menu

For the complete story, click here.


Cures 2015

HINJ issued a statement regarding the passage of the 21st Century Cures Act in the U.S. House of Representatives on July 10.

“[HINJ] applauds the U.S. House of Representatives’ passage of the 21st Century Cures Act,” HINJ said.

“This landmark legislation would accelerate the pace of discovering new, life-saving treatments and cures for some of the world’s most dreaded diseases,” HINJ said.  “It is vitally important to New Jersey’s life sciences community, where much of this research and discovery takes place, and it is critical to patients around the world who will benefit from its impact.”

“Our state is fortunate to have two New Jersey Members of Congress who played key leadership roles in the development of the 21st Century Cures Act,” HINJ continued.  “We commend Congressmen Frank Pallone, Jr. (D-6) and Leonard Lance (R-7) for their commitment to patients through their work to modernize America’s apparatus for researching, reviewing and approving new life-saving medical therapies, technologies and devices.”

To read HINJ’s complete #Cures2015 statement, click here.


Dean J. Paranicas -- HINJ President & Chief Executive Officer (low-res)

Dean J. Paranicas, President and Chief Executive Officer, HINJ

NJ Spotlight has published an op-ed authored by HINJ President and Chief Executive Officer Dean Paranicas on the subject of patent reform legislation currently pending before the U.S. House of Representatives.  Paranicas writes:

[Life sciences companies] depend on a strong, robust patent system to protect the intellectual property needed to discover these treatments and cures. 

“In 2011, Congress passed, with bipartisan support, the America Invents Act (AIA) …. However, the implementation of specific provisions of the AIA has unintentionally — and unfairly — put patent holders at a disadvantage. …

“Life-sciences companies support efforts to curb the abusive practices of patent trolls, and we will work with Congress to craft legislation that strikes the right balance without undermining the ability of legitimate patent holders to enforce their rights.”

To read Paranicas’ complete op-ed piece, click here.


Lt. Governor Kim Guadagno speaks at NJPAC-HINJ Life Sciences Business Roundtable June 23

Lt. Governor Kim Guadagno speaks at NJPAC-HINJ Life Sciences Business Roundtable June 23

Highlighting New Jersey’s leadership as a home for innovation and as the “Medicine Chest of the World,” Lt. Governor Kim Guadagno on June 23 addressed the New Jersey Performing Arts Center’s (NJPAC) Business Partners “Life Sciences and New Jersey’s Innovation Ecosystem” Roundtable, presented in association HINJ.

Following the Lt. Governor’s opening address, HINJ President and Chief Executive Officer Dean Paranicas moderated a panel that featured:

  • Vincent A. Forlenza, Chairman of the Board, Chief Executive Officer and President, BD (Becton, Dickinson & Company)
  • Brenton L. Saunders, CEO and President, Allergan plc
  • Christopher J. Molloy, Ph.D, R.Ph., Senior Vice President, Research and Economic Development, Rutgers, The State University of New Jersey

For the complete story, click here.



Video ChooseNJ 20150618

HINJ President and Chief Executive Officer Dean J. Paranicas was one of the state leaders included in Choose New Jersey’s new video — “Leaders Choose New Jersey: Highly Educated, Perfectly Located” — that premiered at the 2015 BIO International Convention, which was held June 15-18 in Philadelphia.

Other New Jersey leaders appearing in the video to promote the state as a winning place for life sciences companies to invest are Governor Chris Christie, Lt. Governor Kim Guadagno, Michele Brown of ChooseNJ, Aaron Graff of Ferring Pharmaceuticals, Debbie Hart of BioNJ, Dr. Chris Molloy of Rutgers University, and Dr. Jay Tischfield of RUCDR Infinite Biologics.

To view the 4:17-minute video, click here

For the complete story, click here.


Andrew Kitchenman reports in NJ Spotlight that the U.S. House of Representatives’ 21st Century Cures Act is attracting bipartisan support — including from New Jersey sponsors Reps. Frank Pallone (D-6) and Leonard Lance (R-7) — and is drawing praise across New Jersey’s research community, as well as its biotechnology and pharmaceutical industries.

HINJ President and Chief Executive Officer Dean Paranicas commended Congressmen Pallone and Lance for their leadership, and said that the Cures 2015 bill is “vitally important to New Jersey’s life sciences community, but more importantly, to patients around the world.”

Paranicas singled out the FDA Safety Over Sequestration (SOS) (H.R. 1078) provisions sponsored by Congressman Lance.

For the complete story, click here.


The Courier-Post has published an op-ed authored by Debbie Hart, BioNJ President and CEO, and Dean J. Paranicas, HINJ President and Chief Executive Officer.  Hart and Paranicas serve as two of the co-chairs of We Work for Health New Jersey.

“New Jersey’s representatives in Washington have long recognized the importance of fostering and protecting the innovation environment that is critical to finding the next generation of treatments and cures,” Hart and Paranicas wrote.

“We urge our policymakers to continue protecting patients and New Jersey’s economy by rejecting ill-conceived and anti-innovation proposals that could detrimentally impact our state’s economic well-being, and, more importantly, patients’ well-being here at home and around the globe,” they concluded.

To read the full op-ed, click here.


HINJ’s Dean Paranicas (l.) and  Congressman Leonard Lance

HINJ President and CEO Dean Paranicas was a guest on Rep. Leonard Lance’s (R-7) “Seventh District Congressional Report,” which will be broadcast on various public broadcast stations in the coming days.

Rep. Lance and Paranicas focused on the life sciences’ impact on the state’s economy; the FDA Safety Over Sequestration (SOS) Act, which seeks to exempt FDA user fees from sequestration; and the 21st Century Cures initiative.

For the full story, click here.


Password Reset

Please enter your e-mail address. You will receive a new password via e-mail.